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In Brief Kung et al. show that the R72 variant of p53 leads to increased obesity and glucose intolerance in mice fed a high-fat diet. They identify two p53 target genes, Tnf and Npc1l1, that are preferentially bound by R72 and that are responsible for this phenotype.
INTRODUCTION
The p53 tumor suppressor protein has a well-established role in the suppression of cancer (Levine and Oren, 2009 ). This protein confers its tumor-suppressive activities predominantly by acting as a transcription factor, transactivating over 200 different target genes. p53 has also been found to be a critical factor governing innate and adaptive immune responses, reproduction, development, neural degeneration, and aging (Chang et al., 2012; Danilova et al., 2008; Levine et al., 2011; Menendez et al., 2013; Poyurovsky and Prives, 2010) . More recently, the relationship between p53 and metabolism has become the focus of new studies, particularly with the revelation that the role of p53 in metabolism may be essential to its tumor suppressor function (Li et al., 2012; Long et al., 2013; Maddocks et al., 2013; Vousden and Ryan, 2009 ). Additionally, considerable evidence points to a crucial role for p53 in metabolic diseases such as cardiovascular disease, obesity, and type 2 diabetes (Minamino et al., 2009; Ortega et al., 2014; Sano et al., 2007; Tavana et al., 2010) .
Genetic polymorphisms arise over time and are largely responsible for population diversity. Though largely considered innocuous, some SNPs can have significant biological consequences (Chen and Shen, 2015; De Iuliis et al., 2015) . The most-common p53 SNP occurs at amino acid codon 72, where the nucleotide sequence CCC or CGC encodes proline (P72) or arginine (R72) at this residue, respectively (rs1042522; P72R). Interestingly, the frequency of the R72 variant is associated with increasing latitude and colder winter temperatures (Beckman et al., 1994; Shi et al., 2009) . A number of studies indicate that the codon 72 polymorphism of p53 alters its function. In response to DNA damage, the P72 variant promotes enhanced cell-cycle arrest (Pim and Banks, 2004; Thomas et al., 1999) , whereas the R72 variant is a superior inducer of apoptosis (Azzam et al., 2013; Bergamaschi et al., 2006; Dumont et al., 2003; Kung et al., 2015) . These studies prompted a number of efforts to correlate the codon 72 polymorphism with cancer risk, but the contribution of this polymorphism to cancer risk is only weakly supported (Whibley et al., 2009) , and genome-wide association studies (GWASs) on the codon 72 SNP of p53 have failed to reveal significant associations of this SNP with cancer risk (http://www.gwascentral.org).
In contrast to the lack of cancer associations, GWAS analyses have uncovered significant associations between the R72 variant and increased BMI (Speliotes et al., 2010) . In addition, large-scale candidate gene analyses have pointed to a role for this SNP in susceptibility to type 2 diabetes (Gaulton et al., 2008) . Importantly, this association was replicated in an independent analysis (Burgdorf et al., 2011) . These studies, combined with the finding that p53 plays a role in insulin resistance in mice (Minamino et al., 2009) , prompted us to use a mouse model for the codon 72 polymorphic variants to shed light on the mechanism whereby these variants influence obesity, metabolism, and diabetic phenotypes. The mouse model uses a ''humanized p53 knockin'' (Hupki) of each variant that recapitulates human phenotypes (Frank et al., 2011; Luo et al., 2001) . To study the association between the codon 72 polymorphism of p53 and diabetes, we studied the response of these mice to a high-fat diet (HFD).
RESULTS

R72 Hupki Mice Develop Excess Adiposity on a HFD
We analyzed isogenic P72 and R72 Hupki mice backcrossed to C57Bl/6J for over ten generations. Young male P72 and R72 mice between 4 and 6 weeks of age were fed a normal chow diet (CD) for 10 weeks, followed by a HFD for 8 weeks (see schematic; Figure 1A ). Compared to P72 mice, R72 mice showed mildly increased weight gain on the CD (p = 0.05). Notably, however, R72 mice showed markedly increased weight gain on the HFD, compared to P72 (p = 0.002 at week 18; Figures 1B and  1C) . The increased weight gain in HFD R72 mice was accompanied by an increased accumulation of fat in both subcutaneous and visceral areas ( Figure 1D , red arrows). Body composition analysis with proton magnetic resonance spectroscopy ( 1 H-MRS) revealed that the body fat content was >20% greater in HFD R72 compared to P72 mice ( Figures 1E and 1F ). There was a modest increase in food consumption by R72 mice during the HFD period ( Figures 1G and 1H ), but analyses in metabolic cages revealed no differences in oxygen consumption, C0 2 release, food intake, physical activity, or other parameters in P72 and R72 mice that might have explained the increased weight gain (Figures S1A-S1G).
R72 Hupki Mice Develop More-Severe Glucose Intolerance and Insulin Resistance on a HFD
To determine whether the codon 72 polymorphism of p53 contributes to the development of phenotypes associated with type 2 diabetes, we performed glucose tolerance tests (GTTs) during the CD and HFD periods. After the CD, no differences in glucose tolerance were observed between P72 and R72 mice (Figures 2A and 2B ). In contrast, after the HFD R72 mice showed significantly more-impaired glucose tolerance compared to P72 mice ( Figures 2C, 2D , and S2A-S2D). Serum insulin levels were higher following fasting and glucose challenge in R72 compared to P72 mice ( Figure 2E ). This result suggested that R72-associated glucose intolerance is unlikely to be due to reduced insulin production. Upon examining the pancreas, we did not see significant differences in islet numbers, ratio of islet-associated endocrine cell populations, or proliferative potential of islet cells between P72 and R72 mice after HFD ( Figures S2E-S2H ). Interestingly, histopathological analysis of these pancreases revealed significantly larger islets in R72 mice (Figures 2F and 2G) . R72 islets also showed increased levels of fibrosis, as assessed by Sirius Red staining; qRT-PCR analyses of genes associated with fibrosis confirmed this result ( Figures 2H-2J ). Moreover, R72 islets also showed increased senescence-associated b-galactosidase (SA-b-gal) ( Figure S2I ). The combined data suggest that, although R72 mice do not show evidence for impaired production of insulin after HFD, they do show signs of pancreatic dysfunction that are often seen in pre-diabetes. These results suggest that impaired glucose tolerance in R72 mice may be due to insulin resistance. To address this issue, a hyperinsulinemic-euglycemic clamp was performed to assess insulin sensitivity in R72 and P72 mice. The basal (fasting) blood glucose concentration and hepatic glucose production (HGP) were similar in R72 and P72 mice ( Figures 2K and 2L ). The glucose-infusion rate (GIR) needed to maintain euglycemia during the clamp was significantly lower in R72 than P72 mice, indicating insulin resistance ( Figure 2M ). There were non-significant reductions of the glucose disposal rate and HGP suppression during the insulin clamp in R72 compared to P72 mice, and the insulin-stimulated uptake of deoxyglucose trended lower in adipose and muscle tissues of R72 mice ( Figures S2J-S2N ), suggesting hepatic and peripheral insulin resistance in R72 mice following a HFD.
R72 Mice Develop Adipose Inflammation and NAFLD after HFD
The inflammatory response plays a critical role in the development of obesity and insulin resistance (Stienstra et al., 2011) . p53 regulates insulin resistance in part through its ability to mediate an inflammatory response in adipose tissue (Minamino et al., 2009 Figures S3C-S3F ). Elevated inflammation is a feature of non-alcoholic steatohepatitis (NASH) (Firneisz, 2014) . NASH and non-alcoholic fatty liver disease (NAFLD) are closely associated with insulin resistance (Gruben et al., 2014) . Moreover, p53 has been implicated in the progression from steatosis to NASH (Tomita et al., 2012) . To demonstrate a connection between hepatic steatosis and insulin resistance in R72 mice, we examined the insulinsignaling pathway in the livers of the mice used for the hyperinsulinemic-euglycemic clamp experiments. The levels of p53 were similar in R72 and P72 livers following a HFD, but the phosphorylation of Akt1, a marker for insulin-signaling activity, was significantly decreased in the livers of R72 mice ( Figures 3I and 3J ). This demonstrates that hepatic insulin resistance is associated with steatosis and fibrosis in HFD R72 mice.
Altered Expression of p53-Regulated Genes in HFD R72 Liver To explore the potential mechanisms underlying HFD-induced alterations in the liver, we performed qRT-PCR to evaluate the expression changes in the livers of HFD-fed mice of genes reported to be regulated by p53, particularly those with roles in the metabolism pathway (Goldstein and Rotter, 2012; Liang et al., 2013) . Our initial analysis of known p53 target genes associated with cell-cycle arrest and apoptosis, including Cdkn1a(p21), Mdm2, Pmaip1 (Noxa), and Dram1 revealed no differences were observed in the expression of Mdm2 and Dram1 between P72 and R72 HFD livers. In contrast, the expression of Cdkn1a(p21) was increased 5-fold, and Pmaip1 (Noxa) was increased 2-fold in the livers of R72 mice, compared to P72 (Figure 4A) . It is of note that both CDKN1A(p21) and PMAIP1 (Noxa) are biomarkers of NAFLD and NASH (Aravinthan et al., 2013; Bechmann et al., 2010) .
These findings prompted us to analyze a larger set of p53-regulated genes in P72 and R72 livers following a HFD. In particular, we analyzed the expression of p53-regulated genes (I) Whole-cell lysates were extracted from livers of Hupki mice after hyperinsulinemic-euglycemic clamp analysis. Lysates were subjected to western blot analysis to detect p53, total Akt, and phosphorylated Akt at serine 473. Gapdh was used as the loading control.
(J) Quantification of signal intensities in (I) obtained using ImageJ software. The level of p53 was normalized to Gapdh, and the level of phosphorylated Akt (p-Akt) was normalized to the level of total Akt. Protein levels in P72 samples were set as 1-fold. Error bars mark SE. The asterisk denotes p < 0.05. See also Figure S3 .
associated with glycolysis (Pgm2, Igfbp3, Prkab2, Sesn1, Sesn2, and Pten), gluconeogenesis (G6pc, Pck2, Aqp3, and Aqp9), lipid metabolism (Ppargc1a, Ppargc1b, Gamt, Pck1, Apom, Lpin1, and Npc1l1), and inflammation (Ccl2, Ccl4, Adgre1(F4/80) , Tnf, Cd68, Cxcl10, Adipoq, and Pde3b) . Among the glycolysis-and gluconeogenesis-associated genes that we tested, there were no marked changes in gene expression, although three genes (Pgm2, Igfbp3, and Prkab2) showed modestly increased expression and three genes (Sesn1, Pten, and Aqp9) showed modestly reduced expression in R72 livers compared to P72 ( Figure 4B ). With regard to lipid-metabolism-associated genes, the R72 livers showed reduced expression of p53-regulated genes that positively regulate fatty acid oxidation (Ppargc1b, Gamt, and Lpin1) and lipid transport/elimination (Pck1 and Apom). Notably, Npc1l1, the main protein responsible for absorption of dietary cholesterol, was expressed 7-fold greater in R72 livers (Figure 4C) . Additionally, there was a clear trend for an increased inflammatory signature in R72 livers. Several pro-inflammatory genes were significantly increased in R72 livers, whereas two anti-inflammatory genes (Adipoq and Pde3b) showed decreased expression ( Figure 4D ). Of these p53-regulated genes, four have been implicated in NAFLD and insulin resistance: PCK1, which is repressed by p53, and TNF, CCL2, and NPC1L1, which are induced by p53 (Hacke et al., 2010; Haukeland et al., 2006; Minamino et al., 2009; Nomura et al., 2009; She et al., 2000; Zhang et al., 2014) . We confirmed the differences in protein level of Pck1, Ccl2, and Tnf by immunohistochemistry and western blotting ( Figures S4A-S4J) . We next performed chromatin immunoprecipitation to determine whether the R72 variant shows increased binding to the p53-response elements in these four genes. Notably, chromatin immunoprecipitation in the livers of HFD mice revealed increased binding of the R72 variant to at least one canonical p53-binding site in the promoters of all four genes, thus revealing increased DNA binding as the mechanism (Figures 4E-4L ).
The Metabolic Phenotype in R72 Mice Is Exacerbated by a HFD
The possibility existed that R72 mice were prone to hepatic fat accumulation, steatosis, and fibrosis on a normal CD, as a result of aging or some other factor. Thus, we examined P72 and R72 male mice on a CD for 18 weeks (long CD or ''LCD''). Similar to what we observed after 10 weeks of CD, R72 mice showed a mild increase in the body mass after LCD, along with a modest increase in body and liver fat accumulation ( Figures 5A-5C and 5F-5I). Importantly, however, the GTT assay revealed no difference in glucose tolerance between P72 and R72 mice after LCD ( Figures 5D and 5E ). Additionally, there was no increase in Adgre1 (F4/80)-positive cells in the R72 adipose tissue compared to P72 (Figures S5A-S5C ) and no evidence of increased inflammatory cells in R72 livers after LCD ( Figures  S5D-S5G ). The gene expression profiles of p53-regulated genes revealed only two genes with modest increase in expression in R72 liver: Ppargc1a and Cdkn1a(p21) (Figures 5J-5L ). These data indicate that the propensity for fat accumulation may be inherent to R72 mice but that the development of hepatic steatosis, fibrosis, and insulin resistance is greatly exacerbated by a HFD.
Tnf and Npc1l1 Are ''Early Responder'' p53-Regulated Genes Induced following a HFD in R72 Livers The physiological phenotypes associated with type 2 diabetes, such as obesity and inflammation, are known to form a positive feedback loop to exacerbate the disease (Ota, 2013) . To gain a clearer picture of the sequence of events mediated by p53 following exposure to a HFD, we used a short-term (7-day) treatment with a HFD (short HFD or ''SHFD'') on 4-week-old male mice of both genotypes. Notably, after SHFD, R72 displayed significantly higher weight increase (Figures 6A-6C ). We next analyzed in the livers of these mice the level of p53 and the expression of p53-regulated genes previously found to be differentially expressed between P72 and R72 after a long-term HFD.
The steady-state level of p53 protein was similar between P72 and R72 before and after SHFD ( Figures S6A and S6B) , and we found no significant differences in the expression of any p53-regulated genes between P72 and R72, prior to exposure to SHFD (Figures S6C-S6E ). After SHFD, three genes showed notable differences between P72 and R72 livers: these were Npc1l1 (3-fold difference), Cdkn1a(p21) (2-fold difference), and Tnf (2-fold difference; Figures 6D-6F) . Due to the differences in Cdkn1a(p21) on LCD shown previously, we chose to focus on Npc1l1 and Tnf ( Figure 5K ). Immunohistochemical analysis of the livers of P72 and R72 mice showed no differences in control mice but markedly increased Tnf staining in R72 mice after SHFD ( Figures 6G and 6I ). This increase was accompanied by a marked accumulation of Tnf-positive cells in R72 adipose tissues ( Figure S6F ), a mild increase of hepatocyte vacuolization (Figure S6G) , and increased fat accumulation in R72 livers, as assessed by Oil Red O staining ( Figures 6H and 6J ). These findings all preceded the signs of increased inflammation, as we detected no differences in the levels of inflammatory cells and macrophages present in the livers of P72 and R72 mice (Figures S6H and S6I) . These results indicate that R72 mice appear to be more vulnerable to HFD-induced fat accumulation in the liver, even with limited exposure to a HFD. Further, these data suggest that genes such as Tnf and Npc1l1 are ''early responders'' to a HFD in R72 livers and that these genes are likely involved with the initiation and subsequent development of NAFLD in R72 mice.
Increased Tnf and Npc1l1 Underlie the R72 Response to a HFD Because small-molecule inhibitors of Tnf and Npc1l1 were readily available, we sought to test whether these inhibitors could alleviate the effects of a short-term HFD (SHFD) in R72 mice. Toward this end, we treated both SHFD-fed P72 and R72 mice with daily treatment of C87, a Tnf inhibitor, or ezetimibe, an Npc1l1 inhibitor ( Figure 7A ). Both inhibitors led to significantly decreased percent weight gain and Oil Red staining (fat accumulation) in R72 mice compared to P72 mice, resulting in complete elimination of the increased fat accumulation ( Figures  7B-7D ) and weight gain ( Figure S7 ) seen in R72 mice fed with a SHFD. These data firmly implicate these two p53-regulated genes in the differential response of R72 mice to a HFD.
DISCUSSION
In human studies, two groups found that the R72 variant of p53 is associated with increased risk for type 2 diabetes (Burgdorf et al., 2011; Gaulton et al., 2008) . However, the underlying basis for this association was unknown. In this work, we took advantage of a mouse model of the codon 72 polymorphism of p53 to address this issue and found that mice possessing the R72 variant of p53 are more obesity prone and that this is associated with pathological changes in multiple tissues ( Figure 7E) . One of the strongest risk factors for type 2 diabetes is obesity (Wang et al., 2005) . R72 Hupki mice gained weight more readily on either CD or HFD compared to P72 mice ( Figure 1B) . Moreover, the increased obesity phenotype in HFD R72 mice coincided with increased glucose intolerance and insulin resistance (Figure 2 ). These data suggest that the R72 variant may predispose individuals to obesity, which subsequently leads to increased susceptibility to type 2 diabetes. In support of this hypothesis, a recent cohort study of over 2,500 Dutch and Finnish subjects found a significant association between R72 and increased waist circumference (Reiling et al., 2012) . Similarly, a separate study showed that the association between BMI and diabetes is much stronger in homozygous R72 individuals (J-L) Total RNA were extracted from livers after LCD and subjected to qRT-PCR to detect mRNA levels of p53-regulated genes associated with (J) lipid metabolism, (K) cell-cycle arrest/senescence/apoptosis, and (L) inflammation; n = 3. Error bars mark SE. The asterisk denotes p < 0.05. See also Figure S5 . (Gloria-Bottini et al., 2011) . A recent study demonstrated that p53 protected against diet-induced obesity by inducing brown fat differentiation (Molchadsky et al., 2013) . Therefore, one possibility based upon our combined findings and information in the literature is that instead of ''promoting'' obesity, the R72 variant may have impaired ability to suppress HFDinduced obesity. Our findings contradict a previous study using an exon 4 knockin mouse model for the codon 72 variants of p53. This study found no significant metabolic differences or pre-diabetic phenotypes in P72 and R72 mice (Reiling et al., 2014) . However, the latter study did not use a HFD, only normal chow, and our data indicate that the phenotypes of P72 and R72 mice are very similar on normal chow. Instead, we find that a HFD effectively reveals the differences in metabolic phenotypes between P72 and R72 mice.
Evolutionarily, P72 first appears in the p53 gene of new world monkeys. Sequencing efforts have failed to detect the presence of R72 in other primates, suggesting that the emergence of modern human species coincided with the initial emergence of R72 (Puente et al., 2006) . Whether this allele was subject to natural selection remains controversial (Beckman et al., 1994; Khan et al., 2011; Sucheston et al., 2011) . Multiple hypotheses have been posed in favor of natural selection, including that the R72 variant promotes optimal implantation and reproduction due to increased transactivation of the implantation factor LIF (Kang et al., 2009) or that it enhances tolerance to colder winter temperatures (Shi et al., 2009) . In light of our experiments showing that R72 favors lipid accumulation and weight gain, we posit that R72 may have emerged during human evolution due to its ability to provide an advantage for environmental adaptations, such as famine and cold exposure. R72 would also be predicted to enhance the success of child-bearing during famine, which supports the fecundity hypothesis. We speculate that our ancestors may have undergone a positive selection for the R72 allele, which favored energy storage, as this would be advantageous during times of famine (Sellayah et al., 2014) . However, in mod- (E) Proposed model of the impact of R72 on obesity and pre-diabetic phenotypes. In R72 mice, a HFD results in obesity and insulin resistance. The effect of a HFD on R72 mice appears to be systematic, causing enlarged islets and fibrosis in the pancreas, increased infiltration of immune cells into adipose and liver tissues, as well as NAFLD. Inhibition of two R72-preferential p53-regulated genes, Tnf and Npc1l1, reduces fat accumulation in the liver. This could be a potential strategy to treat/prevent obesity and metabolic diseases associated with R72 genotype. See also Figure S7. ern society, this positive selection is lost, and instead, the R72 allele is associated with obesity and type 2 diabetes. According to the most-recent genomic sequencing data, the R72 variant of p53 exists in approximately 5.6 billion people worldwide, of which 2.3 billion are homozygous (Abecasis et al., 2012) . With a viable animal model, a better understanding of the mechanisms behind R72-associated obesity and diabetes has become feasible. Because obesity is also a risk factor for some forms of cancer, the association between R72 and obesity may explain the weak but persistent associations found between this codon 72 variant and cancer (Park et al., 2014) .
Mechanistically, our work points to differences in at least two p53-regulated genes as potentially responsible for the obesity, insulin resistance, and NAFLD phenotypes evident in R72 mice. These genes, which show increased induction in the R72 liver at the earliest time points of HFD, but not CD, are Tnf and Npc1l1. Whereas our data clearly indicate that R72 protein binds preferentially to the p53-binding sites in these genes, we have failed to find evidence for differential phosphorylation or protein-protein interactions that may explain this differential binding ability (C.-P.K., unpublished data). Of these two genes, Tnf has been linked with obesity-induced insulin resistance, and recent studies show reduced blood glucose levels in patients treated with TNF inhibitors (Antohe et al., 2012) . Npc1l1 plays a role in cholesterol absorption, and the Npc1l1 inhibitor ezetimibe lowers cholesterol levels and shifts HDL (high-density lipoprotein)-to-LDL (low-density lipoprotein) ratios (Park, 2013) . Our data therefore clarify the potential association of the R72 variant of p53 with body waist circumference and type 2 diabetes. They also indicate that studies of the efficacy of some of these agents, such as TNF and NPC1L1 inhibitors, toward alleviating diabetes in humans may warrant further investigation.
EXPERIMENTAL PROCEDURES
Diet-Induced Obesity
The generation and analysis of Hupki P72 and R72 mice, and backcrossing in a C57Bl/6J background for over ten generations, was described previously (Frank et al., 2011) . The experiments with mice complied with all federal and institutional guidelines as per IACUC protocols. Mice were housed in plastic cages with ad libitum diet and maintained at 22 C with a 12-hr dark/12-hr light cycle. Wild-type C57Bl/6 mice were purchased from The Jackson Laboratory. Normal CD was obtained from LabDiet (Pico-Vac Diet 20; 3.75 kcal/gm; 21% fat calories). The HFD was customized and purchased from Harlan Laboratories (TD. 130886; 4.4 kcal/g; 49% fat calories). Mouse weight and food consumption were monitored weekly throughout the duration of the experiments. Body composition (lean and fat mass) was measured with nuclear magnetic resonance spectroscopy (Echo MRI 3-in-1 analyzer). For rescue experiments with inhibitors, prior to 7-day exposure to a HFD, 5-week-old mice were weighed and then administered with tumor necrosis factor alpha (TNF-a) inhibitor C87 (10 mg/kg; EMD Millipore; 530796) or NPC1L1 inhibitor ezetimibe (10 mg/kg; Cayman Chemical; 16331) via intraperitoneal (i.p.) injection and oral gavage, respectively. Treatments were performed daily, and mice were weighed and euthanized for liver harvesting by the end of 7-day period.
GTT and Insulin ELISA Mice were fasted overnight for 16 hr in cages with paper bedding. Each mouse was weighed, and glucose dose was calculated for 2 mg/kg body weight (glucose solution was prepared in 0.9% NaCl). Concentration of blood glucose of each mouse was determined by glucometer (OneTouch Ultra; LifeScan) in tail vein blood at time 0 before glucose was administered through i.p. injection. After injection, blood glucose level was measured at 15, 30, 45, 60, 90 , and 120 min. For the insulin ELISA, mice were fasted overnight for 16 hr in cages with paper bedding. Glucose challenge was performed by i.p. injection at 2 mg/kg body weight. Blood was collected before the injection and at 10 min after the injection. Blood samples were kept at room temperature for 15 min and subject to centrifugation at 13,000 g for 10 min. Insulin concentration was measured in serum using an Ultra-Sensitive Mouse Insulin ELISA Kit (Crystal Chem; 90080).
Hyperinsulinemic-Euglycemic Clamp
Hyperinsulinemic-euglycemic clamp and radioisotopic tracer kinetic studies were done to evaluate insulin sensitivity in the whole body, as well as the liver, adipose tissue, and muscle as described previously (Carr et al., 2013) . The mice were anesthetized, and the right internal jugular vein was cannulated. After 4 days of recovery to the pre-surgery weight, the mice were fasted for 6 hr (7 a.m.-1 p.m.) and a bolus intravenous injection of 5 mCi of [3-3 H] glucose was administered, followed by continuous intravenous infusion at 0.05 mCi/min. Baseline glucose kinetics was measured for 120 min followed by hyperinsulinemic clamping for 120 min. A priming dose of regular insulin (16 mU/kg; Humulin; Eli Lilly) was given intravenously, followed by a continuous infusion at 2.5 mU/kg/min. Blood glucose level was maintained at 140 mg/dl via a variable infusion of 20% glucose. 2-deoxy-D-[1-14 C] glucose was injected 45 min before the end of the clamping, and blood samples were collected to estimate glucose uptake. The mice were euthanized, and liver, epididymal white adipose tissue (WAT), and gastrocnemius muscle were excised, frozen immediately in liquid nitrogen, and stored at À80 C for analysis of glucose uptake.
Statistical Analysis
Data are expressed as means ± SEM. For statistical analysis, data were analyzed by two-sided unpaired Student's t test (GraphPad Prism), ANOVA post hoc test with Bonferroni's adjustment (for GTT AUC analysis), or mixed effect models for longitudinal data analysis (for the trends of weight gain between groups). Data were considered significant if p < 0.05. 
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